Danaher Execs Face Investor Suit Over Post-Pandemic Slump

By Katryna Perera · January 25, 2024, 9:30 PM EST

Shareholders of global science and technology company Danaher claim its top brass misled them about increased revenue growth during the onset of the COVID-19 pandemic and failed to inform them that...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

In re Danaher Corporation Derivative Litigation

Case Number

Court

Delaware

Nature of Suit

Stockholders Suits

Date Filed

January 24, 2024

Recent Articles By Katryna

May 30, 2024
Veradigm Execs Sued Over Company's Nasdaq Delisting
May 20, 2024
iRhythm Brass Face Suit Over FDA's Heart Monitor Inquiry
May 02, 2024
Masimo Hit With Derivative Suit Over Audio Co. Acquisition
May 01, 2024
Insulin Pump Maker Wins Toss of Investor Suit For Now
April 30, 2024
Vaxart Investors Want Sanctions Over Deleted Texts
April 08, 2024
Walmart Beats Investor Suit Over Opioid Probe Disclosures
March 29, 2024
Hedge Fund Beats Vaxart Investor's 'Short-Swing' Profits Suit
March 18, 2024
Biotech Ardelyx Beats Shareholder Suit Over Kidney Drug
March 11, 2024
Illumina Brass Faces Shareholder Suit Over Grail Deal Debacle
February 15, 2024
Citadel Securities, Others Beat Biotech Spoofing Suit, For Now